Lead sponsor
Anders Fink-Jensen, MD, DMSci
5 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 1, 2026.
5
Trials led
3
Active
488
Total enrollment
7
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 2
3
Phase 4
2
Trials by status
Recruiting
2
Active, not recruiting
1
Completed
2
Trials led
TrialKey I/E criterionPhaseStatusEnrollment
Does GLP-1RA Prevent Deterioration of Metabolic State in Prediabetic and Diabetic Patients Treated With Antipsychotic Medication?BMI ≥25Ph 4Active, not recruiting104